Biolexis Therapeutics uses an AI-driven MolecuLern process to identify novel chemical entities (NCEs) across protein classes with wet‑lab validation, aiming to shorten discovery timelines from years to months. The company is clinical-stage with a development pipeline focused on metabolic drug candidates targeting disorders such as obesity and diabetes. Biolexis reports 40 active discovery programs and 10 programs in IND‑enabling stages, and its leadership has filed over 20 INDs and secured more than 100 patents. The recent financing will be used to advance the development pipeline, expand operations, and accelerate clinical development of key candidates. Founders/lead scientists include Drs. Bearss and Vankayalapati, whose prior company Montigen Pharmaceuticals was backed by the lead investor before being sold.

Total raised

$10M

Funding rounds

1

Latest round

Series A

Latest activity

Dec 2023